Allogene Therapeutics (ALLO) Price/OCF Ratio: History & Chart

Allogene Therapeutics, Inc.(ALLO)

Biotechnology · South San Francisco, CA

$1.49-0.01 (-1.00%)

Delayed quote: Oct 6, 2026, 9:40 AM EDT

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.

South San Francisco, CA

151 employees

www.allogene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Zachary Roberts

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Allogene Therapeutics, Inc. (ALLO)	$516.01M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$521.60M	N/A	0.26	0.26	0.26
Crescent Biopharma, Inc. (CBIO)vs ›	$542.67M	N/A	N/A	N/A	N/A
NeoGenomics, Inc. (NEO)vs ›	$491.93M	22.31	23.17	204.78	202.88
Bright Minds Biosciences Inc. (DRUG)vs ›	$489.55M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$538.28M	392.90	294.84	294.84	294.84
Immix Biopharma, Inc. (IMMX)vs ›	$540.48M	N/A	N/A	N/A	N/A
Cerus Corporation (CERS)vs ›	$479.63M	198.44	142.73	100.92	100.92
Evolus, Inc. (EOLS)vs ›	$480.08M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$546.13M	27.88	30.64	39.07	39.07

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Allogene Therapeutics, Inc. (ALLO)

$516.01M

N/A

Altimmune, Inc. (ALT)vs ›

$521.60M

N/A

0.26

Crescent Biopharma, Inc. (CBIO)vs ›

$542.67M

N/A

NeoGenomics, Inc. (NEO)vs ›

$491.93M

22.31

23.17

204.78

202.88

Bright Minds Biosciences Inc. (DRUG)vs ›

$489.55M

N/A

908 Devices Inc. (MASS)vs ›

$538.28M

392.90

294.84

Immix Biopharma, Inc. (IMMX)vs ›

$540.48M

N/A

Cerus Corporation (CERS)vs ›

$479.63M

198.44

142.73

100.92

Evolus, Inc. (EOLS)vs ›

$480.08M

N/A

Delcath Systems, Inc. (DCTH)vs ›

$546.13M

27.88

30.64

39.07

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

ALLO Price/OCF Ratio Metrics

ALLO Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics